TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
謝宜璋Hsieh, I-Chang
- 計畫主持人
- 執行臨床試驗年資 22 年 9 個月
-
v12001@cgmh.org.tw
-
hsiehic@ms28.hinet.net
發表文獻
37筆
11
Li YH, Hsieh IC, Ueng KC, Wang YC, Cheng SM, Wu CK, Wu CJ, Hsieh MH, Jen HL, Chang CJ, Chen YH. Antithrombotic Treatment of Stable Coronary Artery Disease. Acta Cardiol Sin. 2021; 37(6):574-579. doi: 10.6515/ACS.202111_37(6).20210513A. (SCI; IF = 2.672; Cardiac & Cardiovascular Systems 98/196)
12
Chen DY, Su PJ, See LC, Liu JR, Chuang CK, Pang ST, Tseng CN, Chen SW, Hsieh IC, Chu PH, Lin YC, Hsu CL, John Chang WC, Lin MS, Pang JS, Hsieh MJ, Huang WK. 2Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study. Prostate. 2021 Sep;81(12):902-912. Epub 2021 Jul 1. (SCI; IF = 4.104; Urology & Nephrology 19/119)
13
Liu HT, Hsieh MJ, Chen CC, Ho MY, Yeh JK, Chang SH, Wang CY, Chen DY, Tsai ML, Hsieh IC*. Comparison of Acute and Long-term Outcomes of Drug-eluting Stents for Aorto-ostial Lesions at the Left Main and Right Coronary Arteries. J Taiwan Cardiovasc Interv 2021; 10:1-8.
14
Lin YS, Tsai ML, Hsieh IC, Wen MS, Wang CY*. Deficiency of circadian gene cryptochromes in bone marrow-derived cells protects against atherosclerosis in LDLR -/- mice. FASEB J. 2021 Feb;35(2): e21309. doi: 10.1096/fj.202001818RRR. (SCI; IF = 5.192; Biology 19/113)
15
Ho MY#, Chen PW#, Feng WH, Su CH, Huang SW, Cheng CW, Yeh HI, Chen CP, Huang WC, Fang CC, Lin HW, Lin SH, Hsieh IC*, Li YH*. Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy. PLoS One. 2021 May 12;16(5): e0251109. (SCI; IF = 3.240; Multidisciplinary Sciences 29/128)
16
Chen DY, Tseng CN, Hsieh MJ, Lan WC, Chuang CK, Pang ST, Chen SW, Chen TH, Chang SH, Hsieh IC, Chu PH, Wen MS, Chen JS, John Chang WC, See LC, Huang WK*. Comparison Between Non–vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals with Cancer-Associated Venous Thromboembolism. JAMA Netw Open. 2021 Feb; 4(2): e2036304. (SCI; IF = 8.485; Medicine, General & Internal 11/315)
17
Tan JW, Chew DP, Abdul Kader MAS, Ako J, Bahl VK, Chan M, Park KW, Chandra P, Hsieh IC, Huan DQ, Johar S, Juzar DA, Kim BK, Lee CW, Lee MK, Li YH, Almahmeed W, Sison EO, Tan D, Wang YC, Yeh SJ, Montalescot G. 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y 12 Receptor Antagonists in the Asia-Pacific Region. Eur Cardiol. 2021 Mar 2;16: e02. eCollection 2021 Feb.
18
Her AY, Shin ES, Bang LH, Nuruddin AA, Tang Q, Hsieh IC, Hsu JC, Kiam OT, Qiu C, Qian J, Ahmad WAW, Ali RM. Drug-coated balloon treatment in coronary artery disease: Recommendations from an Asia-Pacific Consensus Group. Cardiol J. 2021;28(1):136-149.Epub 2019 Sep 30. (SCI; IF = 2.737; Cardiac & Cardiovascular Systems 83/142)
19
Feng WH, Hsieh IC, Li YH. P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: Is It Safe to Abandon Aspirin? Acta Cardiol Sin 2021 Jan; 37(1): 1–8. (SCI; IF = 2.672; Cardiac & Cardiovascular Systems 98/196)
20
Lee CH, Liu KS, Cheng CW, Chan EC, Hung KC, Hsieh MJ, Chang SH, Fu X, Juang JH, Hsieh IC, Wen MS, Liu SJ. Codelivery of Sustainable Antimicrobial Agents and Platelet-Derived Growth Factor via Biodegradable Nanofibers for Repair of Diabetic Infectious Wounds. ACS Infect Dis. 2020 Oct 9;6(10):2688-2697. (SCI; IF =5.084; Infectious Disease 10/118)
